Johnson & Johnson Enterprise Innovation Inc.
Quick facts
Phase 3 pipeline
- JNJ-90301900 (NBTXR3) · Oncology
NBTXR3 is a nanoparticle hafnium oxide that concentrates radiation dose within tumor cells, enhancing the cytotoxic effects of radiotherapy.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: